Sleep Stack (DSIP / Epitalon)
Status
No approved product. No FDA-approved labeling exists for either component or the combination. Neither is an approved medicine in the United States.
What it is
A community pairing aimed at sleep, with weak evidence on both parts.
What published research measured
Combines delta sleep-inducing peptide with the pineal tetrapeptide epitalon. The evidence problem here is unusually clear-cut. DSIP's sleep-promoting effect, despite its name, was not reliably reproduced after the original reports and several human studies found no significant change in sleep architecture. Epitalon sits inside the Khavinson bioregulator programme; this entry cites no registered clinical trial and no independent replication. This entry cites no study of any blend in this category as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time. Combining two compounds whose individual effects on sleep are unestablished does not produce an established effect on sleep.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.